Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|May 30, 2017
Treatment of EGFR Mutant Non-Small Cell Lung Cancer
Treatment of EGFR Mutant Non-Small Cell Lung Cancer
Advertisement
- 65-year-old male, former smoker (25 pack-years, quit 12 years ago) presented complaining of persistent lower back pain, extreme fatigue, shortness of breath, and a 25-lb weight loss in the past 6 months.
- PMH includes rheumatoid arthritis which significantly limits his physical activity.
- Back pain also limited the patient’s daily activity.
- MRI of the spine showed evidence of multiple lesions, but none were causing cord compression.
- CT of the chest showed a 4-cm mass in the left lung, with enlarged bilateral mediastinal lymph nodes.
- The MRI of the brain revealed no metastases.
- ECOG PS was assessed to be 2.
- He underwent an endobronchial ultrasound-directed biopsy of the mediastinal lymph nodes.
- Pathology revealed poorly differentiated adenocarcinoma.
- Molecular testing showed a mutation in EGFR exon19 deletion.
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5